Cargando…
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for treating patients with high-grade serous ovarian cancer. These treatments may be more appropriately directed to patients who might respond if the tumor tissue is additionally tested by next-generation s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069205/ https://www.ncbi.nlm.nih.gov/pubmed/32164585 http://dx.doi.org/10.1186/s12885-020-6693-y |